Expiration date: 08/2026
Composition
1 ampoule contains ondansetron (in the form of hydrochloride dihydrate) 2 mg
Packaging
5 ampoules of 2 ml
Pharmacological action
Antiemetic. Ondansetron effectively prevents and eliminates nausea and vomiting, occurring on the background of anticancer chemotherapy or radiation therapy, as well as in the postoperative period. The mechanism of action is due to the ability of ondansetron selectively block serotonin 5-HT3-receptors. I believe that in the occurrence of nausea and vomiting in anticancer therapy important role played by the stimulation of afferent fibers of the vagus nerve by serotonin released from enterochromaffin cells of gastrointestinal mucosa. Blocking 5-HT3 receptors, ondansetron prevents gag reflex. In addition, ondansetron oppresses the Central links of the gag reflex by blocking 5-HT3 receptors bottom of the IV ventricle (area postrema).
Testimony
Prevention of nausea and vomiting in the conduct of anticancer chemotherapy or radiation therapy, prevention and treatment of nausea and vomiting in the postoperative period.
Contraindications
Hypersensitivity, impairment of liver function, surgery on the abdomen, pregnancy (especially first 3 months), breast-feeding (at the time of treatment), child age: up to 2 years in the case of anesthesia, to 4 years in chemotherapy, the entire age group is in radiation therapy and appointment suppositories.
Application of pregnancy and breastfeeding
Ondansetron is contraindicated in the first trimester of pregnancy. If necessary, use during lactation should stop breastfeeding.
Method of application and doses
Ondansetron is introduced into/in (infusion), in/m. Adults with moderate emetogenna chemotherapy and radiation therapy original: 8 mg, once in/in slowly just before the beginning of the course and again after 8-12 hours, in adults and adolescents 12 years and older can be entered by infusion over 15 min, 32 mg as a single dose 30 minutes before the start of the course or 0.15 mg/kg 3 times for 30 min prior to chemotherapy and then through 4 and 8 h.
Special instructions
When used in patients with mild and severe disorders of liver function is not recommended to exceed the dose 8 mg/day. With careful use of Ondansetron in surgical interventions on the abdominal cavity, as its use may mask progressive ileus.
Drug interactions
Because ondansetron is metabolized enzyme system of the liver (cytochrome P450), requires caution when used together with inducers of CYP2D6 and CYP3A isozymes of cytochrome P450 (barbiturates, carbamazepine, griseofulvin, nitrous oxide, papaverine, phenylbutazone, phenytoin, and probably other hydantoins, rifampin, tolbutamide) and with inhibitors of P450 isoenzymes CYP2D6 and CYP3A (allopurinol, antibiotics-macrolides, anti-depressants, MAO inhibitors, chloramphenicol, cimetidine, estrogensoderjaschie oral contraceptives, diltiazem, disulfiram, erythromycin, valproic acid, sodium valproate, fluconazole, fluoroquinolones, isoniazid, ketoconazole, lovastatin, metronidazole, omeprazole, propranolol, quinidine, quinine, verapamil).
Overdose
Symptoms: increased severity of adverse reactions.
Treatment: symptomatic therapy. The specific antidote is unknown.
Storage conditions
In protected from light place, at temperature not above 25 °C.
Shelf life
2 years.
